Table 5 Results for cost-effectiveness and cost-utility analyses
Sample size | Cost difference in Euros (95% CI) | Effect difference (95% CI) | ICER | Distribution cost-effectivess plane (%NE/SE/SW/NW) | |||
|---|---|---|---|---|---|---|---|
I | C | ||||||
Main analysis (CEA1) | 181 | 159 | LDL-C | −237 (−1,386 to 130) | −0.14 (−0.34 to 0.07) | 1,729 | 22.5/68.5/7.1/1.9 |
181 | 159 | QALY | −237 (−1,386 to 130) | −0.002 (−0.02 to 0.01) | 145,899 | 9.7/30.9/44.2/15.2 | |
Complete case analysis (CEA2) | 118 | 100 | LDL-C | −364 (−2,030 to 238) | −0.14 (−0.37 to 0.08) | 2,012 | 4.6/8.0/55.7/31.7 |
157 | 136 | QALY | −301 (−1,680 to 109) | −0.003 (−0.03 to 0.03) | 100,347 | 6.5/25.4/52.5/15.6 | |
Intervention costs as in RCT (CEA3) | 181 | 159 | LDL-C | −88 (−1,248 to 277) | −0.14 (−0.34 to 0.07) | 645 | 39.4/51.6/5.5/3.6 |
181 | 159 | QALY | −88 (−1,248 to 277) | −0.002 (−0.02 to 0.01) | 54,426 | 17.1/23.4/33.8/25.7 | |
Hospital admission costs excluded (CEA4) | 181 | 159 | LDL-C | 94 (−6 to 193) | −0.14 (−0.34 to 0.07) | −690 | 88.5/2.4/0.5/8.5 |
181 | 159 | QALY | 94 (−6 to 193) | −0.002 (−0.02 to 0.01) | −33,676 | 38.9/1.2/1.7/58.2 | |